We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+4.24%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$5.08B
AUM Growth
-$217M
Cap. Flow
+$248M
Cap. Flow %
4.88%
Top 10 Hldgs %
55.13%
Holding
68
New
14
Increased
10
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$183M
2
CBAY
Cymabay Therapeutics
CBAY
+$92M
3
EVH icon
Evolent Health
EVH
+$76.1M
4
APGE icon
Apogee Therapeutics
APGE
+$43.6M
5
SPRY icon
ARS Pharmaceuticals
SPRY
+$42.3M

Top Sells

Rank Stock Value
1
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$365M
2
ASND icon
Ascendis Pharma A/S
ASND
+$47.3M
3
CTKB icon
Cytek Biosciences
CTKB
+$44M
4
DSGN icon
Design Therapeutics
DSGN
+$18.7M
5
CVAC
CureVac
CVAC
+$14.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HOWL icon
51
Werewolf Therapeutics
HOWL
$17.9M
$13.2M 0.26%
6,144,881
– –
CELC icon
52
Celcuity
CELC
$4.28B
$12.8M 0.25%
1,400,001
– –
NKTR icon
53
Nektar Therapeutics
NKTR
$2.38B
$11.1M 0.22%
+1,246,667
New +$12M
NKTX icon
54
Nkarta
NKTX
$154M
$10.8M 0.21%
7,805,129
– –
BDTX icon
55
Black Diamond Therapeutics
BDTX
$99.4M
$10.1M 0.2%
3,525,754
– –
CMPS
56
Compass Pathways
CMPS
$1.52B
$9.52M 0.19%
+1,286,000
New +$11.4M
SLDB icon
57
Solid Biosciences
SLDB
$790M
$8.63M 0.17%
3,426,286
– –
IGMS
58
DELISTED
IGM Biosciences
IGMS
$7.83M 0.15%
937,500
– –
TRML
59
DELISTED
Tourmaline Bio
TRML
$6.75M 0.13%
240,324
+7,006
+3% +$205K
CMRX
60
DELISTED
Chimerix, Inc.
CMRX
$6.24M 0.12%
+6,501,624
New +$7.08M
THRD
61
DELISTED
Third Harmonic Bio
THRD
$6.15M 0.12%
+961,863
New +$5.88M
CNTB
62
Connect Biopharma Holdings
CNTB
$124M
$5.73M 0.11%
6,991,003
– –
UNCY icon
63
Unicycive Therapeutics
UNCY
$138M
$2.98M 0.06%
+347,069
New +$3.25M
NSTG
64
DELISTED
NanoString Technologies, Inc.
NSTG
$2.96M 0.06%
1,723,373
– –
MGNX icon
65
MacroGenics
MGNX
$243M
$1.59M 0.03%
+342,000
New +$1.7M
NAMSW icon
66
NewAmsterdam Pharma Warrant
NAMSW
$69M
$633K 0.01%
333,333
– –
DSGN icon
67
Design Therapeutics
DSGN
$799M
– –
-2,971,231
Closed -$18.7M
DICE
68
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
– –
-7,856,612
Closed -$365M
1 2
3

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, RA Capital Management held 68 positions worth $5.08B, down 4.1% from $5.3B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

RA Capital Management deployed $248M of net new capital in Q3 2023, opening 14 new positions and adding to 10 existing holdings. Its largest new stake was Cymabay Therapeutics: 6,940,000 shares worth $103M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $47.3M trimmed.

  • RA Capital Management's largest Q3 2023 buy was Cymabay Therapeutics: 6,940,000 shares worth $103M.
  • RA Capital Management added most to Immunogen Inc in Q3 2023, an estimated $183M increase.
  • RA Capital Management's biggest Q3 2023 reduction was Ascendis Pharma A/S, cutting an estimated $47.3M.
  • RA Capital Management fully exited DICE Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $365M.
  • RA Capital Management's ten largest holdings make up 55% of its $5.08B portfolio in Q3 2023.
  • RA Capital Management opened 14 new positions and closed 2 in Q3 2023.
  • RA Capital Management's portfolio value fell 4.1% quarter-over-quarter to $5.08B.

Based on RA Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.